

AMENDMENT TO THE SPECIFICATION:

On page 1 of the specification, lines 8-12, the text is amended as follows:

--- Related Applications

This non-provisional application is a divisional application of U.S. Serial no. 08/828,683 filed March 31, 1997, now issued as US Patent No. 6,469,144, which is a continuation-in-part application of U.S. Serial no. 08/625,328 filed April 1, 1996 and U.S. Serial no. 08/710,802 filed September 23, 1996, the contents of which are incorporated herein by reference. ---

On page 11, lines 10-11, the text is amended as follows:

-- Figure 1 shows the nucleotide sequence of human Apo-2LI cDNA (SEQ ID NO:5) and its derived amino acid sequence (SEQ ID NO:1). --

On page 11, lines 12-14, the text is amended as follows:

--Figures 2A-2B shows an alignment of the amino acid sequence encoded by clone 18.1 of Apo-2 ligand inhibitor (amino acids 34-181 of SEQ ID NO:1) with extracellular regions of other members of the human TNF receptor family: hTNFR1 (SEQ ID NO:12); hTNFR2 (SEQ ID NO:13); hTNFRrp (SEQ ID NO:14); hFas/Apo1 (SEQ ID NO:15); hLNGFR (SEQ ID NO:16); hCD40 (SEQ ID NO:17); hCD27 (SEQ ID NO:18); hCD30 (SEQ ID NO:19); hOX40 (SEQ ID NO:20). --

On page 11, lines 18-24, the text is amended as follows:

-- Figures 4A-4C shows the nucleotide sequence of human Apo-3 cDNA (SEQ ID NO:9) and its derived amino acid sequence (SEQ ID NO:6). The putative signal sequence and transmembrane domain are underlined, the death domain sequence is boxed, and the potential N-linked glycosylation sites are marked with an asterisk. Also boxed is the alanine residue which was present in the fetal lung but not in the fetal heart cDNA clone (discussed in Example 4 below). ---

On page 11, lines 25-26, the text is amended as follows:

-- Figure 5 shows an alignment and comparison of the ECD sequences of native sequence human Apo-3 (amino acids 1-197 of SEQ ID NO:9), TNFR1 (SEQ ID NO:21), and Fas/Apo-1/CD95 (SEQ ID NO:22). ---

On page 11, lines 27-29, the text is amended as follows:
--- Figure 6 shows an alignment and comparison of the death domain sequences of native sequence human Apo-3 (amino acids 338-411 of SEQ ID NO:9), TNFR1 (SEQ ID NO:23), Fas/Apo-1/CD95 (SEQ ID NO:24), FADD (SEQ ID NO:25), TRADD (SEQ ID NO:26), RIP (SEQ ID NO:27), and Drosophila Reaper (SEQ ID NO:28). ---

On page 51, lines 23-34, the text is amended as follows:
---- Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, ~~Rockville, Maryland~~ Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63]. ---

On page 60, lines 26-33, the text is amended as follows:
---- All restriction enzymes referred to in the examples were purchased from New England Biolabs and used according to manufacturer's instructions. All other commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, ~~Rockville, Maryland~~ Manassas, Virginia. ---

On page 73, lines 3-5, the text is amended as follows:
---- The following materials have been deposited with the American
Type Culture Collection, ~~42301 Parklawn Drive, Rockville, MD 10801~~
University Blvd., Manassas, Virginia, USA (ATCC) : ----

Please delete the Sequence Listing appearing on pages 75-89 of
the specification, as originally filed, and enter the substitute
Sequence Listing enclosed herewith which identifies SEQ ID NOS: 1-28.